Scotiaderm Inc.
2020
We are currently raising $1.5M Seed funding to complete Class III Natural Product clinical studies to obtain 'novel claims' for our new active agent, which will differentiate it from all competitive products on the market. With those funds, we are also preparing to manufacture, hire a CSMO and B2B Beta Market across Canada. Validation from BioPort, which provided us with our first pitching opportunity in November 2019, would support our efforts to raise those funds and move forward quickly.
